{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T16:03:15Z","timestamp":1791043395571,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"JSPS KAKENHI Grant","award":["22K15813"],"award-info":[{"award-number":["22K15813"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Stereotactic body radiotherapy (SBRT) boost is a promising treatment for cervical cancer patients who are ineligible for intracavitary brachytherapy (ICBT). The aim of this multicenter, single-arm, phase I\/II study was to prospectively evaluate the efficacy and toxicity of SBRT boost.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>ICBT-ineligible patients with untreated cervical cancer were enrolled. Patients underwent whole-pelvic radiotherapy (45\u00a0Gy in 25 fractions) with SBRT boost to the primary lesion. In the phase I dose-escalation cohort (3\u2009+\u20093 design), patients were treated with SBRT boost of 21 or 22.5\u00a0Gy in three fractions. Although dose-limiting toxicity was not confirmed, a dose of 21\u00a0Gy was selected for the phase II cohort because it was difficult to reproduce the pelvic organs position in two patients during the phase I trial. The primary endpoint was 2-year progression-free survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-one patients (phase I, n\u2009=\u20093; phase II, n\u2009=\u200918) were enrolled between April 2016 and October 2020; 17 (81%) had clinical stage III\u2013IV (with para-aortic lymph node metastases) disease. The median (range) follow-up was 40 (10\u201384) months. The initial response was complete response in 20 patients and partial response in one patient. The 2-year locoregional control, progression-free survival, and overall survival rates were 84%, 67%, and 81%, respectively. Grade\u2009\u2265\u20093 toxicity was confirmed in one patient each in the acute (diarrhea) and late (urinary tract obstruction) phases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These findings suggested that a SBRT boost is more effective than the conventional EBRT boost and can be an important treatment option for ICBT-ineligible patients with cervical cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Study registration<\/jats:title>\n                <jats:p>This study was registered at the University Hospital Medical Information Network Clinical Trials Registry (UMIN000036845).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11604-024-01566-8","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T06:01:56Z","timestamp":1713247316000},"page":"909-917","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Phase I\/II study of stereotactic body radiotherapy boost in patients with cervical cancer ineligible for intracavitary brachytherapy"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5792-3795","authenticated-orcid":false,"given":"Kei","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Furusawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko Nemoto","family":"Murofushi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Kino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiharu","family":"Yasugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Uno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Karasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"key":"1566_CR1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.brachy.2011.07.003","volume":"11","author":"AN Viswanathan","year":"2012","unstructured":"Viswanathan AN, Thomadsen B, American Brachytherapy Society Cervical Cancer Recommendations Committee, American Brachytherapy Society. American brachytherapy society consensus guidelines for locally advanced carcinoma of the cervix Part I: General principles. Brachytherapy. 2012;11:33\u201346.","journal-title":"Brachytherapy"},{"key":"1566_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ijrobp.2013.05.033","volume":"87","author":"K Han","year":"2013","unstructured":"Han K, Milosevic M, Fyles A, Pintilie M, Viswanathan AN. Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biol Phys. 2013;87:111\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1566_CR3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/jjco\/hyy187","volume":"49","author":"K Ito","year":"2019","unstructured":"Ito K, Shimizuguchi T, Karasawa K. Clinical outcomes following conventional external beam radiotherapy boost in Japanese patients with cervical cancer who are ineligible for intracavitary brachytherapy. Jpn J Clin Oncol. 2019;49:270\u20135.","journal-title":"Jpn J Clin Oncol"},{"key":"1566_CR4","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.rpor.2018.08.005","volume":"23","author":"L Yanez","year":"2018","unstructured":"Yanez L, Ciudad AM, Mehta MP, Marsiglia H. What is the evidence for the clinical value of SBRT in cancer of the cervix? Rep Pract Oncol Radiother. 2018;23:574\u20139.","journal-title":"Rep Pract Oncol Radiother"},{"key":"1566_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13014-020-1469-8","volume":"15","author":"E Leung","year":"2020","unstructured":"Leung E, Gladwish A, Sahgal A, Lo SS, Kunos CA, Lanciano RM, et al. Survey of current practices from an international task force for gynecological stereotactic ablative radiotherapy. Radiat Oncol. 2020;15:24.","journal-title":"Radiat Oncol"},{"key":"1566_CR6","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.clon.2017.01.009","volume":"29","author":"LC Mendez","year":"2017","unstructured":"Mendez LC, Leung E, Cheung P, Barbera L. The role of stereotactic ablative body radiotherapy in gynaecological cancers: a systematic review. Clin Oncol (R Coll Radiol). 2017;29:378\u201384.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"1566_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/IGC.0000000000001200","volume":"28","author":"B O\u2019Donnell","year":"2018","unstructured":"O\u2019Donnell B, Shiao JC, Pezzi TA, Waheed N, Sharma S, Bonnen MD, et al. Stereotactic body radiation therapy, intensity-modulated radiation therapy, and brachytherapy boost modalities in invasive cervical cancer: a study of the national cancer data base. Int J Gynecol Cancer. 2018;28:563\u201374.","journal-title":"Int J Gynecol Cancer"},{"key":"1566_CR8","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/jjco\/hyz074","volume":"49","author":"K Ito","year":"2019","unstructured":"Ito K, Kito S, Nakajima Y, Shimizuguchi T, Ogawa H, Nihei K, et al. Determining the recommended dose of stereotactic body radiotherapy boost in patients with cervical cancer who are unsuitable for intracavitary brachytherapy: a phase I dose-escalation study. Jpn J Clin Oncol. 2019;49:856\u201361.","journal-title":"Jpn J Clin Oncol"},{"key":"1566_CR9","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/jjco\/hyr096","volume":"41","author":"T Toita","year":"2011","unstructured":"Toita T, Ohno T, Kaneyasu Y, Kato T, Uno T, Hatano K, et al. A consensus-based guideline defining clinical target volume for primary disease in external beam radiotherapy for intact uterine cervical cancer. Jpn J Clin Oncol. 2011;41:1119\u201326.","journal-title":"Jpn J Clin Oncol"},{"key":"1566_CR10","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1093\/jjco\/hyp191","volume":"40","author":"T Toita","year":"2010","unstructured":"Japan Clinical Oncology Group, Toita T, Ohno T, Kaneyasu Y, Uno T, Yoshimura R, Kodaira T, et al. A consensus-based guideline defining the clinical target volume for pelvic lymph nodes in external beam radiotherapy for uterine cervical cancer. Jpn J Clin Oncol. 2010;40:456\u201363.","journal-title":"Jpn J Clin Oncol"},{"key":"1566_CR11","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ygyno.2012.04.036","volume":"126","author":"T Toita","year":"2012","unstructured":"Toita T, Kitagawa R, Hamano T, Umayahara K, Hirashima Y, Aoki Y, et al. Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule. Gynecol Oncol. 2012;126:211\u20136.","journal-title":"Gynecol Oncol"},{"key":"1566_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.radonc.2004.12.015","volume":"74","author":"C Haie-Meder","year":"2005","unstructured":"Haie-Meder C, P\u00f6tter R, Van Limbergen E, Briot E, De Brabandere M, Dimopoulos J, et al. Recommendations from gynaecological (GYN) GEC-ESTRO working group\u2606(I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol. 2005;74:235\u201345.","journal-title":"Radiother Oncol"},{"key":"1566_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"1566_CR14","unstructured":"US department of health and human services. common terminology criteria for adverse events (CTCAE) version 4.0, https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_40 [accessed 15 January 2021]."},{"key":"1566_CR15","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018ezr\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"1566_CR16","unstructured":"National Comprehensive Cancer Network. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology. https:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp. Accessed 15 Jan 2021."},{"key":"1566_CR17","unstructured":"The Physician Date Query of National Cancer Institute (PDQ-NCI) [National Cancer Institute Web site]. https:\/\/www.cancer.gov\/types\/cervical; 2021. Accessed 15 Jan 2021."},{"key":"1566_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.prro.2016.01.012","volume":"6","author":"J Croke","year":"2016","unstructured":"Croke J, Fyles A, Barbera L, D\u2019Souza D, Pearcey R, Stuckless T, et al. Radiation therapy quality-of-care indicators for locally advanced cervical cancer: a consensus guideline. Pract Radiat Oncol. 2016;6:315\u201323.","journal-title":"Pract Radiat Oncol"},{"key":"1566_CR19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.radonc.2017.03.005","volume":"123","author":"LC Mendez","year":"2017","unstructured":"Mendez LC, Weiss Y, D\u2019Souza D, Ravi A, Barbera L, Leung E. Three-dimensional-guided perineal-based interstitial brachytherapy in cervical cancer: a systematic review of technique, local control and toxicities. Radiother Oncol. 2017;123:312\u20138.","journal-title":"Radiother Oncol"},{"key":"1566_CR20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.clon.2005.10.004","volume":"18","author":"EP Saibishkumar","year":"2006","unstructured":"Saibishkumar EP, Patel FD, Sharma SC, Karunanidhi G, Sankar AS, Mallick I. Results of external-beam radiotherapy alone in invasive cancer of the uterine cervix: a retrospective analysis. Clin Oncol (R Coll Radiol). 2006;18:46\u201351.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"1566_CR21","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ijrobp.2019.10.042","volume":"106","author":"K Albuquerque","year":"2020","unstructured":"Albuquerque K, Tumati V, Lea J, Ahn C, Richardson D, Miller D, et al. A phase II trial of stereotactic ablative radiation therapy as a boost for locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2020;106:464\u201371.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1566_CR22","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.brachy.2016.06.006","volume":"15","author":"T Tamaki","year":"2016","unstructured":"Tamaki T, Noda SE, Ohno T, Kumazaki Y, Kato S, Nakano T. Dose-volume histogram analysis of composite eqd2 dose distributions using the central shielding technique in cervical cancer radiotherapy. Brachytherapy. 2016;15:598\u2013606.","journal-title":"Brachytherapy"},{"key":"1566_CR23","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3897\/folmed.62.e47920","volume":"62","author":"C Iavazzo","year":"2020","unstructured":"Iavazzo C, Iatrakis G, Iavazzo PE, Bakalianou K, Gkegkes ID. Elderly patients with gynecological cancer: Is the management individualized? Folia Med (Plovdiv). 2020;62:438\u201343.","journal-title":"Folia Med (Plovdiv)"},{"key":"1566_CR24","doi-asserted-by":"publisher","first-page":"e377","DOI":"10.1016\/j.prro.2018.05.010","volume":"8","author":"S Venigalla","year":"2018","unstructured":"Venigalla S, Guttmann DM, Horne ZD, Carmona R, Shabason JE, Beriwal S. Definitive local therapy is associated with improved overall survival in metastatic cervical cancer. Pract Radiat Oncol. 2018;8:e377\u201385.","journal-title":"Pract Radiat Oncol"},{"key":"1566_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13014-019-1297-x","volume":"14","author":"Z Yin","year":"2019","unstructured":"Yin Z, Lou H, Tang H, Ni J, Zhou Q, Chen M. Efficacy of radical doses of pelvic radiotherapy for primary tumor treatment in patients with newly diagnosed organ metastatic cervical cancer. Radiat Oncol. 2019;14:82.","journal-title":"Radiat Oncol"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-024-01566-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-024-01566-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-024-01566-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T07:59:45Z","timestamp":1722239985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-024-01566-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1566"],"URL":"https:\/\/doi.org\/10.1007\/s11604-024-01566-8","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,16]]},"assertion":[{"value":"26 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kei Ito was a member of the advisory board and has received honorariums from Varian Medical Systems K. K. The other authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}